Scientific Publications by FDA Staff
Expert Rev Mol Diagn 2012 Jul;12(6):603-20
Hotspot oncomutations: implications for personalized cancer treatment.
Myers MB, Wang Y, McKim KL, Parsons BL
Understanding the extent to which specific tumor mutations impact or mediate patient response to particular cancer therapies has become a rapidly increasing area of research. Recent research findings regarding four predominant mutational targets (KRAS, BRAF, EGFR and PIK3CA) show that these tumor mutations have predictive power for identifying which patients are likely to respond to particular therapies, and have prognostic significance irrespective of treatment. However, in this regard, the literature is frequently nuanced and sometimes contradictory. This lack of clarity may be due, at least in part, to the utilization of mutation detection methods with varying sensitivities across studies of different patient populations. Nevertheless, considerable evidence suggests minor tumor subpopulations may be contributing to inappropriate patient stratification, development of resistance to treatment, and the relapse that often follows treatment with molecularly targeted therapies. Consequently, mutant tumor subpopulations need to be considered in order to improve strategies for personalized cancer treatment.
|Category: Journal Article, Review|
|PubMed ID: #22845481||DOI: 10.1586/erm.12.51|
|Includes FDA Authors from Scientific Area(s): Toxicological Research|
|Entry Created: 2012-08-01||Entry Last Modified: 2012-12-12|